Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Winqvist M, Andersson PO, Asklid A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L, Österborg A; Swedish CLL Group.

Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4. No abstract available.

2.

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Sylvan SE, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, Kimby E, Norin S, Andersson PO, Karlsson C, Karlsson K, Lauri B, Mattsson M, Sandstedt AB, Strandberg M, Österborg A, Hansson L.

Haematologica. 2019 Apr;104(4):797-804. doi: 10.3324/haematol.2018.200204. Epub 2018 Nov 22.

3.

[Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice].

Henriksson R, Falkenius J, Norin S, Öhman D, Abrahamsson M, Lindquist M, Lööv SÅ.

Lakartidningen. 2017 Nov 6;114. pii: ETTF. Swedish.

4.

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A.

Haematologica. 2016 Dec;101(12):1573-1580. Epub 2016 May 19.

5.

Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study.

Sylvan SE, Skribek H, Norin S, Muhari O, Österborg A, Szekely L.

Exp Hematol. 2016 Jan;44(1):38-49.e1. doi: 10.1016/j.exphem.2015.08.009. Epub 2015 Aug 29.

PMID:
26325331
6.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

7.

Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.

Norin S, Björkstrand B, Rommel F, Timberg L, Andersson PO, Häggström J, Aldrin A, Hansson L.

Leuk Res. 2015 Jan;39(1):33-7. doi: 10.1016/j.leukres.2014.09.019. Epub 2014 Nov 13.

PMID:
25499233
8.

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.

Eketorp Sylvan S, Hansson L, Karlsson C, Norin S, Lundin J, Osterborg A.

Leuk Lymphoma. 2014 Aug;55(8):1774-80. doi: 10.3109/10428194.2013.827786. Epub 2014 Feb 4.

PMID:
24237446
9.

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.

Sylvan SE, Rossmann E, Mozaffari F, Porwit A, Norin S, Karlsson C, Hansson L, Lundin J, Österborg A.

Br J Haematol. 2012 Dec;159(5):608-12. doi: 10.1111/bjh.12077. Epub 2012 Oct 9. No abstract available.

PMID:
23043283
10.

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.

Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grandér D, Lehmann S, Norin S, Shokri F, Rabbani H, Mellstedt H, Österborg A.

Leuk Lymphoma. 2013 Apr;54(4):843-50. doi: 10.3109/10428194.2012.731599. Epub 2012 Oct 9.

PMID:
22988987
11.

Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia.

Yakimchuk K, Norin S, Kimby E, Hägglund H, Warner M, Gustafsson JÅ.

Leuk Lymphoma. 2012 Jan;53(1):139-44. doi: 10.3109/10428194.2011.605187. Epub 2011 Sep 6.

PMID:
21767241
12.

Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.

Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, Rasmussen M, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Geisler C, Juliusson G, Rosenquist R.

Haematologica. 2011 Aug;96(8):1161-9. doi: 10.3324/haematol.2010.039768. Epub 2011 May 5.

13.

Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.

Gunnarsson R, Isaksson A, Mansouri M, Göransson H, Jansson M, Cahill N, Rasmussen M, Staaf J, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Juliusson G, Rosenquist R.

Leukemia. 2010 Jan;24(1):211-5. doi: 10.1038/leu.2009.187. Epub 2009 Sep 10. No abstract available.

PMID:
19741724
14.

Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia.

Norin S, Kimby E, Lundin J.

Med Oncol. 2010 Sep;27(3):820-5. doi: 10.1007/s12032-009-9292-y. Epub 2009 Aug 25.

PMID:
19705305
15.

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.

Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, Johansson E, Mellstedt H, Lundin J, Osterborg A.

Leukemia. 2006 Dec;20(12):2204-7. Epub 2006 Oct 19. No abstract available.

PMID:
17051245
16.

Posttransplant lymphoma--a single-center experience of 500 liver transplantations.

Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Söderdahl G, Hägglund H.

Med Oncol. 2004;21(3):273-84.

PMID:
15456956

Supplemental Content

Support Center